Nektar Therapeutics
NKTR
$73.32
-$2.12-2.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.51% | -18.83% | -37.92% | 28.26% | 30.95% |
| Total Depreciation and Amortization | -64.73% | -76.60% | -76.63% | -79.55% | -69.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 77.19% | 79.98% | 84.62% | -211.57% | -27,163.24% |
| Change in Net Operating Assets | -364.81% | -13,581.02% | -493.30% | -6,578.32% | -262.79% |
| Cash from Operations | -26.43% | -15.20% | -18.67% | -7.46% | -5.81% |
| Capital Expenditure | 19.16% | 32.67% | 40.87% | 50.88% | -89.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -520.05% | -334.56% | -100.23% | -41.32% | 83.54% |
| Cash from Investing | -522.97% | -336.93% | -100.84% | -41.20% | 81.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,677.39% | 3,927.87% | 633.90% | 1,046.81% | 823.53% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -102.56% | -102.56% | -100.00% |
| Cash from Financing | 342,086.62% | 581,955.74% | 328.71% | 237.66% | -99.25% |
| Foreign Exchange rate Adjustments | -90.00% | 133.33% | 250.00% | 234.48% | 110.10% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -124.73% | 1,235.45% | -424.64% | 131.38% | 166.03% |